髋关节类固醇/麻醉剂注射后患者是否更易出现髋骨关节炎进展和股骨头塌陷:一项回顾性观察研究
该回顾性观察研究由两名肌骨放射科医生盲法评估70例髋关节类固醇/麻醉剂注射患者(注射曲安奈德40 mg/0.5%无防腐剂罗哌卡因4 mL)与两个对照组(人口学匹配的髋关节对照70例、盂肱关节注射患者44例)的影像学进展,随访3~12个月。结果显示注射髋关节骨关节炎进展率44%显著高于髋关节对照24%(p=0.02),新发塌陷率17%显著高于髋关节对照1%(p=0.002)和盂肱关节注射患者2%(p=0.02)。作者认为需进一步评估髋关节注射物及注射人群。
要点
- 髋关节类固醇/麻醉剂注射后3~12个月,44%(31/70)出现骨关节炎进展,显著高于髋关节对照的24%(17/70)(p=0.02)。
- 注射髋新发股骨头塌陷17%(12/70),显著高于髋关节对照1%(1/70)(p=0.002)和盂肱关节注射患者2%(1/44)(p=0.02)。
- 髋关节注射与盂肱关节注射患者骨关节炎进展率差异未达统计学显著(44% vs 30%,p=0.17)。
核心结论
- 髋关节类固醇/麻醉剂注射患者在注射后3~12个月比髋关节对照和盂肱关节注射患者更易出现骨关节炎进展和股骨头塌陷;需进一步评估髋关节注射物及注射人群。
研究设计与样本
- 经IRB批准并符合HIPAA的回顾性盲法观察研究,由两名肌骨放射科医生独立评估X线片,分歧由第三名资深读片者裁定;注射组70髋(曲安奈德40 mg/0.5%无防腐剂罗哌卡因4 mL),对照组为人口学匹配的髋关节对照70髋和盂肱关节注射患者44髋;比较采用Fisher精确检验和非配对t检验。
关键影像表现/征象
- 注射髋组31/70(44%)出现骨关节炎进展,髋关节对照组17/70(24%),盂肱关节注射组13/44(30%)。
- 注射髋组12/70(17%)出现新发塌陷,髋关节对照组1/70(1%),盂肱关节注射组1/44(2%)。
诊断标准与关键数值
- 骨关节炎进展率:注射髋组44%(31/70)vs 髋关节对照组24%(17/70),差异有统计学意义(p=0.02);注射髋组44% vs 盂肱关节注射组30%(13/44),差异无统计学意义(p=0.17)。
- 新发塌陷率:注射髋组17%(12/70)vs 髋关节对照组1%(1/70),差异有统计学意义(p=0.002);注射髋组17% vs 盂肱关节注射组2%(1/44),差异有统计学意义(p=0.02)。
局限性
- 原文结论指出需进一步评估髋关节注射物及注射人群(Further evaluation of hip injectates and the injection population is warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate progression of osteoarthritis and femoral head articular surface collapse in hip steroid/anesthetic injection patients (HIPs).
MATERIALS AND METHODS: This study was IRB-approved and HIPAA-compliant. Two musculoskeletal radiologists performed retrospective, blinded reviews of radiography for 70 HIPs (40 mg triamcinolone/4 mL 0.5% preservative-free ropivacaine) with a 3- to 10-month follow-up and two control groups: demographic-matched patients with similar hip radiograph follow-up duration but no injection; and glenohumeral joint injection patients. Discordant evaluations were adjudicated by a third, senior reader. Groups were compared using Fisher's exact and unpaired t tests.
RESULTS: There were 70 HIPs (mean age 67 ± 17 (range 19-92) years; 44 women, 26 men), who were followed for a mean of 6 ± 2 (3-12) months. Thirty-one (31 out of 70, 44%) of HIPs had progression of osteoarthritis after injection, versus 17 out of 70 (24%) of hip controls (HCs) and 13 out of 44 (30%) of glenohumeral injection patients (GIPs). This difference between HIPs and HCs was statistically significant (p = 0.02) but not that between HIPs and GIPs (0.17). Twelve (12 out of 70, 17%) HIPs had new collapse, compared with 1 out of 70 (1%) of HCs and 1 out of 44 (2%) of GIPs. This difference was statistically significant (HCs: p = 0.002; GIPs: p = 0.02).
CONCLUSION: Hip steroid/anesthetic injection patients are more likely to demonstrate osteoarthritis progression and femoral head collapse than HC and GIPs in the injected joint 3-12 months after steroid and anesthetic injection. Further evaluation of hip injectates and the injection population is warranted.
引用
- Simeone FJ, Vicentini JRT, Bredella MA, et al. Are patients more likely to have hip osteoarthritis progression and femoral head collapse after hip steroid/anesthetic injections? A retrospective observational study. Skeletal Radiol. 2019. PMID: 30840099. doi:10.1007/s00256-019-03189-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。